These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 15608991)

  • 1. [Randomized intravascular ultrasound comparison between endoprostheses with and without amorphous silicon-carbide].
    Tanajura LF; Sousa JE; Sousa AG; Abizaid A; Paula JE; Albertal M; Feres F; Mattos LA; Staico R; Pinto IM
    Arq Bras Cardiol; 2004 Dec; 83 Spec No():59-63. PubMed ID: 15608991
    [No Abstract]   [Full Text] [Related]  

  • 2. Silicon carbide-coated stents in patients with acute coronary syndrome.
    Hamm CW; Hugenholtz PG;
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):375-81. PubMed ID: 14571490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis.
    Dussaillant GR; Mintz GS; Pichard AD; Kent KM; Satler LF; Popma JJ; Wong SC; Leon MB
    J Am Coll Cardiol; 1995 Sep; 26(3):720-4. PubMed ID: 7642865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A paclitaxel-eluting stent for the prevention of coronary restenosis.
    Park SJ; Shim WH; Ho DS; Raizner AE; Park SW; Hong MK; Lee CW; Choi D; Jang Y; Lam R; Weissman NJ; Mintz GS
    N Engl J Med; 2003 Apr; 348(16):1537-45. PubMed ID: 12700373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of quantitative angiographic parameters with the magnitude of neointimal hyperplasia measured by volumetric intravascular ultrasound in patients treated with bare metal and nonpolymeric paclitaxel-coated stents.
    Mintz GS; Hong MK; Raizner AE; Lee CW; Kim JJ; Escolar E; Fearnot NE; Park SW; Park SJ; Weissman NJ
    Am J Cardiol; 2005 Jan; 95(1):105-7. PubMed ID: 15619403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intimal hyperplasia regression from 6 to 12 months after stenting.
    Kuroda N; Kobayashi Y; Nameki M; Kuriyama N; Kinoshita T; Okuno T; Yamamoto Y; Komiyama N; Masuda Y
    Am J Cardiol; 2002 Apr; 89(7):869-72. PubMed ID: 11909579
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravascular ultrasound stent area of sirolimus-eluting stents and its impact on late outcome.
    Cheneau E; Pichard AD; Satler LF; Suddath WO; Weissman NJ; Waksman R
    Am J Cardiol; 2005 May; 95(10):1240-2. PubMed ID: 15878001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study.
    Nunes GL; Abizaid AC; Theodoro MP; Brito FS; Caixeta A; da Silva LF; Mazzotti NG; Belló-Klein A; Clausell N
    Am Heart J; 2006 Nov; 152(5):914.e1-7. PubMed ID: 17070157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial.
    Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Staico R; Feres F; Centemero M; Tanajura LF; Abizaid A; Pinto I; Maldonado G; Seixas A; Costa MA; Paes A; Mintz GS; Sousa JE
    Circulation; 2004 Feb; 109(7):861-6. PubMed ID: 14757690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents.
    Mintz GS; Hong MK; Raizner AE; Lee CW; Kim JJ; Escolar E; Fearnot NE; Park SW; Park SJ; Weissman NJ
    Am J Cardiol; 2005 Jan; 95(1):107-9. PubMed ID: 15619404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
    Grube E; Sonoda S; Ikeno F; Honda Y; Kar S; Chan C; Gerckens U; Lansky AJ; Fitzgerald PJ
    Circulation; 2004 May; 109(18):2168-71. PubMed ID: 15123533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-arginine supplementation does not inhibit neointimal formation after coronary stenting in human beings: an intravascular ultrasound study.
    Dudek D; Legutko J; Heba G; Bartus S; Partyka L; Huk I; Dembinska-Kiec A; Kaluza GL; Dubiel JS
    Am Heart J; 2004 Apr; 147(4):E12. PubMed ID: 15077095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study.
    Cheneau E; Wu Z; Leborgne L; Ajani AE; Weissman N; Pichard AD; Satler LF; Kent KM; Mintz G; Waksman R
    Am Heart J; 2003 Jul; 146(1):142-5. PubMed ID: 12851623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and efficacy of tandem positioning on angiographic and clinical outcomes in the Intimal Hyperplasia Inhibition with Beta In-Stent Trial.
    Shirai K; Lansky AJ; Mintz GS; Costantini CO; Cristea E; Fahy M; Vandertie L; Yeung A; Raizner AE; Waksman R; Leon MB
    Am J Cardiol; 2003 May; 91(9):1113-5. PubMed ID: 12714158
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral sirolimus after bare metal stent implantation.
    Rodriguez A; Fernández-Pereira C; Rodriguez-Alemparte M
    Catheter Cardiovasc Interv; 2006 Aug; 68(2):333-4; author reply 335. PubMed ID: 16821241
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcome.
    Unverdorben M; Sippel B; Degenhardt R; Sattler K; Fries R; Abt B; Wagner E; Koehler H; Daemgen G; Scholz M; Ibrahim H; Tews KH; Hennen B; Berthold HK; Vallbracht C;
    Am Heart J; 2003 Apr; 145(4):e17. PubMed ID: 12679775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo in Europe (BRIDGE).
    Serruys PW; Wijns W; Sianos G; de Scheerder I; van den Heuvel PA; Rutsch W; Glogar HD; Macaya C; Materne PH; Veldhof S; Vonhausen H; Otto-Terlouw PC; van der Giessen WJ
    J Am Coll Cardiol; 2004 Aug; 44(3):528-37. PubMed ID: 15358015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
    Radke PW; Figulla HR; Drexler H; Klues HG; Mügge A; Silber S; Daniel W; Schmeisser A; Reifart N; Motz W; Büttner HJ; Fischer D; Ortlepp JR; Schaefers K; Hoffmann R; Hanrath P;
    Am Heart J; 2006 Oct; 152(4):761.e1-6. PubMed ID: 16996855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.
    Katayama T; Ueba H; Tsuboi K; Kubo N; Yasu T; Kuroki M; Saito M; Momomura S; Kawakami M
    Am Heart J; 2007 May; 153(5):762.e1-7. PubMed ID: 17452150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
    Takagi T; Yamamuro A; Tamita K; Yamabe K; Katayama M; Mizoguchi S; Ibuki M; Tani T; Tanabe K; Nagai K; Shiratori K; Morioka S; Yoshikawa J
    Am Heart J; 2003 Aug; 146(2):E5. PubMed ID: 12891212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.